Aclarion (ACON) shares rallied sharply early Monday after the healthcare technology company said it has established a commercial agreement with Scripps Health that will add its Nociscan technology platform to treat lower back pain to Scripps facilities in San Diego.
The agreement is expected to optimize Scripps' clinical treatment by providing Aclarion's magnetic resonance spectroscopy signal processing and allowing physicians to non-invasively distinguish between lumbar discs causing pain and non-painful discs, the companies said.
Financial terms were not disclosed.
Aclarion shares climbed by more than 125% in early trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。